1. Introduction {#sec1}
===============

Cancer is a major public health problem and about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide according to the GLOBOCAN estimates \[[@B1]\]. The development and progression of cancer is a multistage process and alterations of oncogenes, tumor suppressor genes, and stability genes are responsible for tumorigenesis \[[@B2]\]. Tumor suppressor gene*p53* is one of the most frequently mutated genes and numerous studies have reported that the*p53* mutations play an important role in human cancers \[[@B3]--[@B6]\].

The*mouse double minute 2* (*MDM2*) gene encodes a protein which could negatively regulate the activity of p53 tumor suppressor protein by binding to the latter and leading to its ubiquitination \[[@B7], [@B8]\]. Elevated MDM2 levels have been detected in several human cancers even though with wild-type*p53* due to the abnormal expression of*MDM2* gene and/or protein \[[@B9], [@B10]\], which suggested as an alternative way for p53 inactivation in tumorigenesis \[[@B11]\]. Therefore, polymorphisms and mutations affecting MDM2 expression may contribute to the susceptibility to various cancers.

Two functional SNPs have been discovered which are located in the*MDM2* intronic promoter (P2): SNP309 (rs2279744 T\>G) \[[@B12]\] and SNP285 (rs117039649 G\>C) \[[@B13]\] located 24 base pairs upstream of SNP309. Compared with the SNP309T allele, the G-variant of SNP309 increases MDM2 transcription through enhancing the binding of the transcription factor Sp1 \[[@B12]\]. In contrast, the presence of SNP285C allele would reduce the binding strength between Sp1 and the*MDM2* promoter in comparison with the SNP285G allele \[[@B13]\]. Although the presence of the SNP285C variants seems to antagonize the effect of SNP309G \[[@B13]\], there are some contradictory studies about*MDM2* SNP285 in different types of cancers \[[@B13]--[@B22]\]. One of the possible reasons may be the relatively small sample size in individual published studies. Hence, we performed a meta-analysis to provide a more precise estimation of the relationship between*MDM2* SNP285 polymorphism and cancer risk.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

We systematically searched all relevant articles from PubMed, Embase, and Chinese Biomedical (CBM) databases using the search terms: "*MDM2* or*mouse double minute 2*", "variant or polymorphism or variation", and "cancer or carcinoma or tumor or neoplasm" (last search was updated on May 19, 2016). We also checked all references of relevant reviews and eligible articles for additional studies. Only the latest or the largest study would be included in the current meta-analysis if studies were carried out with the same or overlapped subjects.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Studies included in the meta-analysis had to meet the following criteria: (a) evaluating the association between*MDM2* SNP285 polymorphism and cancer risk; (b) case-control design; (c) written in English or Chinese; (d) providing sufficient data to calculate odds ratios (ORs) with corresponding 95% confidence intervals (CIs).

The following exclusion criteria were used: (a) case-only studies or case reports; (b) conference abstracts, reviews, or meta-analysis; (c) duplicate publications; and (d) no available data reported.

2.3. Data Extraction {#sec2.3}
--------------------

Two authors (Ping Wang and Meilin Wang) independently extracted data from all the publications according to the inclusion and exclusion criteria. Disagreements were resolved through discussion until a consensus was reached. The following information was extracted from each study: first author\'s surname, year of publication, country of origin, ethnicity, cancer type, control source, total number of cases and controls, genotype methods, and numbers of cases and controls with the GG, GC, and CC genotypes. Ethnic backgrounds were categorized as Caucasians, Africans, or Mixed which contained more than one ethnic group.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Crude ORs and their corresponding 95% CIs were used to evaluate the strength of associations between*MDM2* polymorphism and cancer risk. The pooled ORs were estimated for*MDM2* SNP285 polymorphism under the dominant model (CC+GC*versus* GG), heterozygous model (GC*versus* GG), and allele comparison (C*versus* G). Chi-square-based *Q* test was used to assess the heterogeneity between studies, and *P* \< 0.10 was considered as significant heterogeneity exists. The fixed-effects model (the Mantel-Haenszel method) \[[@B23]\] was used when there was no significant heterogeneity; otherwise, the random-effects model (the DerSimonian and Laird method) \[[@B24]\] would be applied. Potential publication bias was assessed by the funnel plot as described previously \[[@B25]\]. The asymmetry of the funnel plot was evaluated using Egger\'s linear regression test \[[@B26]\]. Subgroup analysis was performed by cancer type (if one cancer type contained only one study, it would be merged into the "other" group), ethnicity, and sample size (\<500 and ≥500). Sensitivity analysis was used to evaluate the effect of individual investigations on the overall cancer risk by excluding each investigation individually and recalculating the ORs and the 95% CIs \[[@B27]\]. All the statistical tests were performed with Stata (version 12.0; Stata Corporation, College Station, TX). All *P* values were two-sided, and a *P* \< 0.05 was considered as statistically significant.

3. Results {#sec3}
==========

3.1. Study Characteristics {#sec3.1}
--------------------------

As shown in [Figure 1](#fig1){ref-type="fig"}, a total of 1,282 published records were retrieved by using the search terms described above, consisting of 542 related studies from PubMed, 690 from Embase (494 overlapped studies were deducted), and 50 studies from CBM database. After rigorous assessment of abstracts and contents, only 14 publications met the crude inclusion criteria and were subjected for further evaluation. Of these 14 publications, four were excluded for being without detailed data for further evaluation \[[@B28]--[@B31]\], and a total of 10 publications met the inclusion criteria \[[@B13]--[@B22]\]. Of the 10 publications, one publication \[[@B18]\] with two ethnic groups was separated as two independent studies, two publications \[[@B13], [@B16]\] with two cancer types were separated as two independent studies, and one publication \[[@B21]\] with four cancer types was also separated as four independent studies. A total of 10 publications including 16 studies were included in the final meta-analysis ([Table 1](#tab1){ref-type="table"}).

For those studies \[[@B13], [@B15], [@B16], [@B21]\] that used the same control group, the control numbers were only calculated once in the total number of controls, and overlapped controls and cases were subtracted from the total number. Overall, 16 published studies of 14,573 cases and 9,115 controls were included in the final meta-analysis. Of the 16 studies, sample sizes of case ranged from 119 to 2501, in which four studies focused on breast cancer, three on lung cancer, two on ovarian cancer, prostate cancer, and cervical cancer, and others (colon cancer, hepatocellular carcinoma, and endometrial cancer) with only one study. There were 13 studies on Caucasians, two studies on mixed ethnicity, and only one study on Africans. Of all the studies, 14 were population-based, while two were hospital-based, 7 studies with sample size less than 500 and 9 studies with sample size greater than 500. Most of the cases were histologically confirmed and controls were mainly matched for sex, age, and ethnicity.

3.2. Meta-Analysis Results {#sec3.2}
--------------------------

The overall results for the*MDM2* SNP285 polymorphism and cancer risk are shown in [Table 2](#tab2){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}. We found that there was a significant association between SNP285 polymorphism and overall cancer risk with the heterozygous model (OR = 0.89, 95% CI = 0.79--0.99), and reduced ORs were observed with other genetic models (dominant: OR = 0.90, 95% CI = 0.79--1.01 and allele comparison: OR = 0.91, 95% CI = 0.80--1.03) but not reaching statistical significance. In subgroup analysis by cancer type, a significantly decreased risk was found for ovarian cancer (heterozygous: OR = 0.77, 95% CI = 0.63--0.94; dominant: OR = 0.76, 95% CI = 0.63--0.93; and allele comparison: OR = 0.77, 95% CI = 0.63--0.93), and a much lower OR was observed for breast cancer than that for lung and prostate cancer under all three genetic models. Stratification analysis by ethnicity revealed a statistically significantly decreased cancer risk for Caucasians with the heterozygous (OR = 0.88, 95% CI = 0.79--0.98) and dominant model (OR = 0.89, 95% CI = 0.79--1.00), and reduced OR was found but not reaching statistical significance with the allele comparison (OR = 0.90, 95% CI = 0.79--1.03). In subgroup analysis by sample size, a significantly decreased risk was found for studies with relatively large sample size under the heterozygous model (OR = 0.92, 95% CI = 0.84--1.00), and reduced ORs were observed but not reaching statistical significance under other genetic models (dominant: OR = 0.93, 95% CI = 0.85--1.02 and allele comparison: OR = 0.94, 95% CI = 0.85--1.04).

3.3. Heterogeneity and Sensitivity Analysis {#sec3.3}
-------------------------------------------

Substantial heterogeneities were observed for the*MDM2* SNP285 polymorphism and risk of cancer under the dominant model (*P* = 0.043) and allele comparison (*P* = 0.014), but not under the heterozygous model (*P* = 0.120). Hence, we used the random-effects model to generate wider CIs. Finally, leave-one-out sensitivity analysis indicated that no single study could alter the pooled ORs obviously (data not shown).

3.4. Publication Bias {#sec3.4}
---------------------

The shape of the funnel plot seemed symmetry for the SNP285 polymorphism ([Figure 3](#fig3){ref-type="fig"}) and no significant publication bias was detected by Egger\'s test for SNP285 polymorphism (dominant model: *P* = 0.939; heterozygous model: *P* = 0.997; and allele comparison: *P* = 0.886). These suggested that publication bias might not have severe influence on the results of the current meta-analysis on the association between*MDM2* SNP285 polymorphism and cancer risk.

4. Discussion {#sec4}
=============

The association between*MDM2* SNP285 polymorphism and cancer risk has been investigated by several research groups, but the conclusions were inconsistent. The most possible reason for the differences between studies is the small sample size in individual studies, which limits the statistical power to detect the real effects of polymorphism. We performed the current meta-analysis to combine the results of all available studies through a systematic search of relevant literatures, which may be useful for evaluating the contribution of SNP285 polymorphism to cancer. In this meta-analysis, which included 16 published studies of 14,573 cases and 9,115 controls, we found that*MDM2* SNP285 polymorphism was significantly associated with a decreased overall cancer risk in the heterozygous model. Furthermore, the subgroup analysis showed that the association was more evident in the studies of ovarian cancer, Caucasians subjects, and relatively large sample size.

MDM2 encodes a protein that binds to and facilitates the degradation of the p53 tumor suppressor protein via the ubiquitination pathway \[[@B32], [@B33]\]. The cellular level of MDM2 controls both the p53 and pRb pathways and keeps the balance between growth arrest, cell death, senescence, and apoptosis; disturbances of these processes contribute to malignant transformation of cell \[[@B34]\]. MDM2 protein levels and function are precisely controlled at the transcription, translational, and posttranslation levels. Therefore, SNPs occurring in the*MDM2* gene could potentially dysregulated both transcription and translation.

The*MDM2* SNP285G\>C is a newly discovered polymorphism, and this is the first report on the association of this polymorphism and cancer risk. It has been suggested that the*MDM2* SNP285C allele might reduce the risk of female cancers (such as breast, ovarian, and endometrial cancer), due to the estrogen receptor (ESR) reported to be as a transcriptional activator with Sp1 \[[@B35]\] and one of the estrogen receptor binding elements (EREs) in the*MDM2* P2 promoter overlapped with the Sp1 binding site harboring SNP285 \[[@B16]\]. In the present meta-analysis, a significantly decreased risk was found between*MDM2* SNP285 polymorphism and ovarian cancer, and a much lower OR was found for breast cancer than that for male cancers (lung and prostate cancer), which was consistent with previous studies.

There are some limitations in our meta-analysis that remain to be addressed. Firstly, there is a limited number of studies that have actually analysed*MDM2* SNP285 polymorphism with cancer susceptibility and the total sample size was relatively small, which may lead to relatively weak power to detect the real association. Secondly, only published studies were included in this meta-analysis. It may be possible that some related unpublished studies as well as literatures published in languages other than English and Chinese were not included, which might lead to a bias to some extent. Thirdly, in the subgroup analysis, only one study was carried out in Africans. This subgroup did not have enough statistical power for us to investigate the real relationship. Fourthly, genotyping methods were different in each study, which will affect the bias. Additionally, our results were based on unadjusted estimates of ORs without adjustment for individual\'s age, sex, smoking status, drinking status, environmental factors, and other lifestyles.

In summary, this meta-analysis suggests that*MDM2* SNP285 polymorphism was significantly associated with a decreased overall cancer risk with the heterozygous model. However, large and well-designed studies are warranted to validate our finding. Moreover, further studies estimating the effect of gene-gene and gene-environment interactions may provide a better, comprehensive understanding of the association between*MDM2* SNP285 polymorphism and cancer risk.
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![Flowchart of included studies for the association between*MDM2* SNP285 polymorphism and cancer susceptibility.](DM2016-4585484.001){#fig1}

![Forest plot of overall cancer risk associated with*MDM2* SNP285 polymorphism by dominant model. For each study, the estimated OR and its 95% CI are plotted with a box and a horizontal line. ⋄, pooled OR and its 95% CIs.](DM2016-4585484.002){#fig2}

![Funnel plot analysis to detect publication bias for SNP285 polymorphism by dominant model. Each point represents a separate study for the indicated association.](DM2016-4585484.003){#fig3}

###### 

Characteristics of studies included in the meta-analysis.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Surname                           Year   Country            Ethnicity   Cancer type   Control\   Genotype method     Number of cases   Number of controls   MAF                                 
                                                                                        source                                                                                                    
  --------------------------------- ------ ------------------ ----------- ------------- ---------- ------------------- ----------------- -------------------- ----- --- ------- ------- ----- --- -------
  Knappskog et al. \[[@B13]\]       2011   Norway and Dutch   Caucasian   Breast        PB         PCR-sequencing      1,973             1,843                130   0   2,518   2,322   196   0   0.039

  Knappskog et al. \[[@B13]\]       2011   Norway and Dutch   Caucasian   Ovarian       PB         PCR-sequencing      832               782                  50    0   2,518   2,322   196   0   0.039

  Paulin et al. \[[@B14]\]          2008   Scotland           Caucasian   Breast        PB         PCR-sequencing      299               278                  18    3   275     263     12    0   0.022

  Bjørnslett et al. \[[@B15]\]      2012   Norway             Caucasian   Ovarian       PB         PCR-sequencing      1,566             1,471                92    3   2,465   2,274   183   8   0.040

  Knappskog et al. \[[@B16]\]       2012   Norway             Caucasian   Endometrial   PB         PCR-sequencing      910               846                  63    1   2,465   2,274   183   8   0.040

  Knappskog et al. \[[@B16]\]       2012   Norway             Caucasian   Prostate      PB         PCR-sequencing      666               608                  55    3   675     623     51    1   0.039

  Piotrowski et al. \[[@B17]\]      2012   Poland             Caucasian   Breast        PB         Sequencing          468               444                  23    1   550     494     54    2   0.053

  Ryan et al. \[[@B18]\]            2012   USA                African     Lung          PB         Taqman              142               139                  3     0   253     250     3     0   0.006

  Ryan et al. \[[@B18]\]            2012   USA                Caucasian   Lung          PB         Taqman              373               351                  21    1   398     373     25    0   0.031

  Rebbani et al. \[[@B19]\]         2014   Morocco            Mixed       HCC           PB         PCR-sequencing      119               115                  4     0   103     101     2     0   0.010

  Vargas-Torres et al. \[[@B20]\]   2014   Brazil             Mixed       Cervical      HB         PCR-RFLP            293               288                  5     0   184     184     0     0   NA

  Gansmo et al. \[[@B21]\]          2015   Norway             Caucasian   Colon         PB         LightSNiP           1,532             1,430                99    3   3,749   3,495   254   0   0.034

  Gansmo et al. \[[@B21]\]          2015   Norway             Caucasian   Lung          PB         LightSNiP           1,331             1,232                98    1   3,749   3,495   254   0   0.034

  Gansmo et al. \[[@B21]\]          2015   Norway             Caucasian   Breast        PB         LightSNiP           1,717             1,614                100   3   1,872   1,750   122   0   0.033

  Gansmo et al. \[[@B21]\]          2015   Norway             Caucasian   Prostate      PB         LightSNiP           2,501             2,319                175   7   1,877   1,745   132   0   0.035

  Roszak et al. \[[@B22]\]          2015   Poland             Caucasian   Cervical      HB         Sanger sequencing   456               430                  25    1   481     431     47    3   0.055
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HB: hospital-based; PB, population-based; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; HCC: hepatocellular carcinoma; MAF: Minor Allele Frequency; NA: not applicable.

###### 

Meta-analysis of the association between *MDM2* SNP285 polymorphism and cancer risk.

  Variables     Number of studies   Heterozygous                Dominant   Allele comparison                                                                                  
  ------------- ------------------- --------------------------- ---------- ------------------- --------------------------- ------- ------ --------------------------- ------- ------
  All^1^        15                  **0.89 (0.79**--**0.99)**   0.120      31.2                0.90 (0.79--1.01)           0.043   42.2   0.91 (0.80--1.03)           0.014   50.0
  Cancer type                                                                                                                                                                  
   Breast       4                   0.81 (0.61--1.08)           0.074      56.8                0.84 (0.61--1.15)           0.033   65.7   0.87 (0.62--1.22)           0.015   71.4
   Lung         3                   1.07 (0.86--1.34)           0.676      0.0                 1.09 (0.87--1.36)           0.726   0.0    1.10 (0.89--1.37)           0.773   0.0
   Prostate     2                   1.02 (0.84--1.25)           0.664      0.0                 1.06 (0.87--1.30)           0.677   0.0    1.10 (0.91--1.34)           0.700   0.0
   Ovarian      2                   **0.77 (0.63**--**0.94)**   0.903      0.0                 **0.76 (0.63**--**0.93)**   0.943   0.0    **0.77 (0.63**--**0.93)**   0.985   0.0
   Others^2^    4                   0.86 (0.66--1.11)           0.175      39.5                0.85 (0.64--1.12)           0.122   48.2   0.84 (0.63--1.14)           0.084   54.8
  Ethnicity                                                                                                                                                                    
   Caucasian    13                  **0.88 (0.79**--**0.98)**   0.088      36.9                **0.89 (0.79**--**1.00)**   0.028   47.7   0.90 (0.79--1.03)           0.008   55.2
   African      1                   1.80 (0.36--9.03)           ---        ---                 1.80 (0.36--9.03)           ---     ---    1.79 (0.36--8.93)           ---     ---
   Mixed        1                   1.76 (0.32--9.79)           ---        ---                 1.76 (0.32--9.79)           ---     ---    1.74 (0.32--9.62)           ---     ---
  Sample size                                                                                                                                                                  
   \<500        6                   0.79 (0.51--1.21)           0.079      49.4                0.84 (0.52--1.35)           0.030   59.5   0.89 (0.54--1.47)           0.012   65.8
   ≥500         9                   **0.92 (0.84**--**1.00)**   0.525      0.0                 0.93 (0.85--1.02)           0.368   8.1    0.94 (0.85--1.04)           0.233   23.6

^1^Vargas-Torres et al. (2014), it was not calculated for these models because the numbers of GC and CC genotypes were zero.

^2^The others included endometrial cancer \[[@B16]\], hepatocellular carcinoma \[[@B19]\], colon cancer \[[@B21]\], and cervical cancer \[[@B22]\].

[^1]: Academic Editor: Lance A. Liotta
